

Severe Acute Respiratory Coronavirus-2 Antibody and T cell response after a third vaccine dose in hemodialysis patients compared with healthy controls

Dr. Benedikt Simon (1, X), Dr. Harald Rubey (1), Dr. Martin Gromann (2), Dr. Astrid Knopf-Völkerer (2), Dr. Boris Hemedi (3), Assoc. Prof. Sonja Zehetmayer (4), Dr. Bernhard Kirsch (2)

Running headline: COVID booster in hemodialysis patients vs controls

(1) Mistelbach-Gänserndorf State Clinic, Institute for Medical-Chemical Laboratory Diagnostics

(2) Mistelbach-Gänserndorf State Clinic, Department for Internal Medicine III – Nephrology and Diabetology

(3) Hainburg State Clinic, Department for Internal Medicine

(4) Center for Medical Statistics, Informatics and Intelligent Systems (Institute of Medical Statistics), MedUni Wien

(X) Corresponding Author: Benedikt Simon, Liechtensteinstraße 67, 2130 Mistelbach; Tel: +43 2572 9004 21504; email: benedikt.simon@mistelbach.lknoe.at

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1. Abstract

Hemodialysis patients (HD patients) have a high health risk from Severe Acute Respiratory Coronavirus-2 (SARS-CoV-2) infection. In this study, we assess the impact of a third vaccine dose (3D) on antibody levels and T cell response in HD patients and compare the results to those of a healthy control group.

We conducted a prospective cohort study consisting of 60 HD patients and 65 healthy controls. All of them received two doses of the Comirnaty mRNA vaccine and a third mRNA vaccine dose (Spikevax or Comirnaty). The SARS-CoV-2 S antibody response in all participants was measured 6 months after the second vaccine dose and 6 to 8 weeks after administration of the 3D. We also assessed INF- γ secretion 6–8 weeks after the 3D in 24 healthy controls, 17 HD patients with a normal and 20 HD patients with a low or no antibody response after the second dose. The groups were compared using univariate quantile regressions and multiple analyses. The adverse effects of vaccines were assessed via a questionnaire.

After the 3D, the SARS-CoV-2-specific antibody and INF- γ titers of most HD patients were comparable to those of healthy controls. A subgroup of HD patients who had shown a diminished antibody response after the first two vaccine doses developed a significantly lower antibody and INF- γ response compared to responder HD patients and controls, even after the 3D. A new strategy is needed to protect this patient group from severe COVID-19 infection.

Keywords: hemodialysis, COVID-19, third vaccine dose

1. Introduction

Severe Acute Respiratory Coronavirus-2 (SARS-CoV-2) is a coronavirus that has led to a pandemic with global consequences. An infection with this virus can cause severe respiratory failure and death¹. Patients undergoing hemodialysis on a regular basis (HD Patients) are especially prone to infection with SARS-CoV-2^{2,3} and a severe course of disease with significantly increased mortality^{4,5}. Consequently, HD patients are prioritized to receive vaccines against COVID-19. Prior studies^{6,7} showed that HD patients exhibit a diminished antibody response after two vaccine doses. Importantly, a subgroup of HD patients were low/non-responders. The T cell interferon gamma (INF- γ) response in HD patients after vaccination has not been characterized very well, although some studies⁸ aim to improve our knowledge on this topic. In Austria, a third dose (3D) of vaccine has been recommended due to the decline of vaccine-induced antibodies and the rise of COVID-19 cases⁹.

The aim of this study is to measure the impact of the third mRNA vaccine on antibody levels and INF- γ response in HD patients 6 to 8 weeks after the 3D and compare these to healthy controls who also received three vaccine shots. Using such data, we aim to assess the differences between the groups and explore whether further measures are needed to adequately protect this high-risk population.

2. Methods

We conducted a prospective cohort study to elucidate the antibody and INF- γ response to vaccination with Comirnaty (BNT-162b2, BioNTech/Pfizer, two doses) and a booster dose of an mRNA vaccine (either Spikevax (mRNA-1273), Moderna or Comirnaty) administered 6 months after the second vaccine dose in HD patients versus healthy controls vaccinated with the same regimen.

2.1 Study Population

HD patients were considered eligible if they were on dialysis for at least 3 months and had received vaccination with Comirnaty (vaccination schedule in Section 2.1.3). The healthy control group consisted of volunteer healthcare workers who had been vaccinated using the same regimen. Participants in both groups needed to be 18–99 years old. Pregnant women and individuals with known SARS-CoV-2 infection in the past (diagnosed via patient history and test for nucleocapsid (N) antibody, see Section 2.3.2) were excluded from the study. The study protocol was approved by the local ethics committee. Written informed consent was obtained.

In all, 81 dialysis patients were initially scheduled to receive the 3D. Of these, four contracted SARS-CoV-2 infection, two were not eligible for vaccination due to high CRP values, three received a transplant, and, sadly, 12 passed away (unrelated to COVID-19). Finally, 60 HD patients were included to receive their 3D.

Of these, 21 were identified as low/non- responders (see Section 2.1.1). In this group, two participants (11%) were women and 16 were men. The median age was 72 years (age range 49–82 years).

The other 39 HD patients were designated “responders”. In this group, 15 participants (38%) were women and 24 were men. The median age was 66 years (age range 34 to 83 years). All HD patients received their 3D 6 months after the second dose.

Initially, 80 volunteer healthcare workers were recruited to receive their 3D in the course of the study. Of these, two delayed their 3D and 13 opted not to test for antibodies after the 3D. Finally, 65 healthy controls were included.

This group consisted of 43 (66%) women and 22 men. The median age was 50 years (age range 29–65 years). All demographic data are summarized in Table 1.

The medical histories of dialysis patients were extracted from medical records, while the control group was assessed using a standardized questionnaire.

	Control group (n = 65)	HD Patients, responders (n = 39)	HD Patients, non-responders (n=21)
Age (y, mean, range)	52 (29–65)	66 (34–83)	71 (49–82)
Women	43 (66%)	15 (38%)	2 (11%)
Risk factors			
Diabetes	2 (3%)	15 (38%)	8 (38%)
COPD	0	10 (26%)	6 (29%)
Hypertension	18 (28%)	33 (85%)	18 (86%)
Primary Kidney Disease			
Diabetes	-	10 (26%)	7 (33%)
Vascular disease	-	18 (46%)	3 (14%)
Glomerulonephritis	-	4 (10%)	4 (19%)
unknown	-	0	0
other	-	7 (18%)	7 (33%)
Medication			
RAAS-Inhibitors usage	0	20 (51%)	6 (29%)
Immunosuppressant usage (Steroids, CNI, MMF)	2 (3%)	3 (8%)	4 (19%)

Vitamin D supplements usage	0	28 (72%)	18 (86%)
EPO usage	0	35 (90%)	18 (86%)

Table 1. Demographics of the study population. COPD, Chronic obstructive pulmonary disease. RAAS, Renin-Angiotensin-Aldosterone system. CNI, Calcineurin inhibitors. MMF, Mycophenolat-Mofetil. EPO, Erythropoietin.

2.1.1 Low/Non- Responders

Twenty-one patients in the HD patient group and none in the healthy control group were identified as low-/non-responders based on their antibody titers being lower than 29 BAU/ml four weeks after the second vaccine, as described in our previous work⁷. Briefly, this cut-off correlated with SARS-CoV-2 neutralization activity of patient sera¹⁰.

2.1.2 Patient selection for SARS-CoV-2 T cell test

The study participants were assigned an anonymization number at the beginning of the study. Some were then randomly selected to receive an INF- γ release assay (IGRA) test due to the limited availability of test kits. From each of the three subjects' groups (controls, HD patient responders and HD patient low/non- responders), patients were selected using a random number generator (RANDOM.ORG) set to generate integers that had a maximum value of 80, 60 and 21 (initial numbers of controls, adjusted numbers of HD patient responders and HD patient low-responders, respectively), repeated for the number of IGRA tests available. The participants whose anonymization numbers corresponded to the value generated received an IGRA test 6–8 weeks after their 3D (24 controls, 17 HD patient responders, 20 HD patient low/non-responders).

2.1.3 Vaccination schedules

All study participants were immunized with two doses of Comirnaty timed 3 weeks between the first and second doses. All study participants received 3D 5 to 6 months after the second dose. Of these participants, 43 controls (66%) received Spikevax (Moderna) and 22 controls (33%) received Comirnaty (Pfizer/BioNTech) as their 3D. Of the 39 responder HD patients, 38 received Spikevax (Moderna) and one received Comirnaty (Pfizer/BioNTech). Of the 21 low-responder patients, 15 received Comirnaty and six received Spikevax.

For a graphical representation, see Figure 1.

2.2 Antibody titers

2.2.1 Processing of blood samples

Blood draws were performed one week prior to and six to eight weeks after administration of the booster dose. Samples were centrifuged on a Hettich Rotanta 460r centrifuge at 3000 rpm for 10 minutes, aliquoted and anonymized. They were then stored at -70°C and thawed prior to testing.

2.2.2 Serological assessment

All samples were analyzed with an Elecsys®Anti-SARS-CoV-2 test for nucleocapsid (N) antibodies. A positive result in this test led to an exclusion from the study due to a high probability of a past SARS-CoV-2 infection.

The antibody response elicited by vaccination was measured using an Elecsys® Anti-SARS-CoV-2 S on a Cobas e 801 platform according to specifications, diluted 100-fold. Results were recorded as ranging from 0 (≤ 0.40 U/ml, lower limit of detection [LOD]) to 25000 (≥ 25000 U/ml, upper LOD) and assigned to anonymized patient data, as in our previous study⁷. Results showing values greater 15BAU/ml were considered positive.

Longitudinal antibody titers were measured from samples collected 21 days, 3 months and 6 months (last collection on the day of the 3D) after the second vaccine dose. Follow-up samples

were taken 6-8 weeks after 3D and 12 weeks after 3D. For the last follow-up, only 16 healthy controls were available.

2.3 SARS-CoV-2 S-specific (IGRA)

2.3.1 Processing of blood samples

In the blood draws for antibody titers 6–8 weeks after the 3D, a second sample was drawn from randomly selected patients (see Section 2.1.2) into a lithium-heparin tube. The whole blood samples were incubated in three test tubes lined with SARS-CoV-2 S antigen at 37°C for 24 hours and then centrifuged on a Hettich Rotanta 460r centrifuge for 10 min at 4000 rpm. The supernatant was then analyzed using the ELISA plates provided by the manufacturer.

2.3.2 IGRA test

The T cell response was assessed using the WANTAI SARS-CoV-2 IGRA assay according to specifications ¹¹. Twenty µl of specimen diluent and 50 µl of reconstituted standard (400pg/ml in serial dilutions of 1:1, 1:2, 1:4, 1:8, 1:16 and 1:32) and the same amount of serum supernatant was used to fill the wells and incubated at 37°C for 1 h. Fifty µl HRP conjugate was added, and after incubation for 1 hour, the plate was washed 5 times using the washing buffer provided by the manufacturer diluted 1:20 and with 1 min soak time between washes. Chromogen A and B solutions were added to the wells, and after 15 min of incubation in the dark at 37°C, a stop solution was applied to all wells. The plate was read in a dual wavelength photometer (450 and 630 nm). The resulting INF-γ concentrations were recorded as ranging from 0 (≤3 pg/ml, LOD), or any of the conditions specified in the test manual as negative) to 400 (≥400 pg/ml, upper LOD) and assigned to anonymized patient data.

2.4 Adverse events

Adverse events (AE) of the 3D for all groups (controls and combined responder and low/non-responder HD patients) were assessed via a standardized questionnaire.

AEs were divided into two categories: local AEs (pain at injection site, redness and/or swelling at injection site and induration at injection site) and systemic AEs (fatigue, headache, muscle and/or joint pain, fever, gastrointestinal symptoms [diarrhea, nausea, vomiting] or other AEs).

Patients were asked to grade their AEs after 3D according to subjective severity. Grading was performed on a scale from 1 to 4. Grade 1 AE signified mild (does not interfere with activity); Grade 2 moderate (interferes with activity); Grade 3 severe (prevents daily activity); and Grade 4 (emergency department visit or hospitalization), analogous to the FDA toxicity grading scale¹².

2.5 Statistics

We investigated the influence of being a member of one of three groups (Controls, HD Patients Low/Non- Responder and HD Patients Responder), sex and age on SARS-CoV-2 RBD-specific antibody titer 6–8 weeks after 3D. Univariate quantile (median) regressions were performed. The quantile regression was chosen due to the skewed distribution of the antibody titer (40 patients with maximum titer observation of 25000BAU/ml, test cut-off). Bootstrap was applied to construct standard errors and perform statistical tests for each independent factor (5000 replications). Pairwise contrasts estimating marginal means (median), standard error (SE) and 95% confidence intervals (CI) were generated for factor variables. P-value adjustment for pairwise comparison of the group variable was performed using the Tukey method. Then, a multiple analysis was computed for all variables with a p-value less than $\alpha = 0.05$ in the univariate analysis.

The influence of sex and age on INF- γ titers was also investigated for the three groups (controls, HD patients responder, HD patients low/non-responder). For this purpose, the same analyses as above were conducted.

The significance level was set to 0.05. The analyses were performed with R 4.1.1 and the R-packages *quantreg* and *emmeans*¹³.

Boxplots and AE bar graphs were created in Excel 2019 (Microsoft).

2.6 Checklist for cohort studies

We used the STROBE cohort checklist when writing our report⁴⁶.

3. Results

3.1 Vaccine antibody titer results after three doses

We analyzed the SARS-CoV2 RBD specific antibody titers of 65 healthcare workers and 60 HD patients. Of the control group, 65/65 (100%) had a titer of >15 BAU/ml 6–8 weeks after their 3D. Of the HD Patients, 58/60 (97%) seroconverted after the 3D (3 months after the second dose: 86% HD patients). A graphical representation is depicted in Figure 2 for the healthy controls and in Figure 3 for the HD patients.

Importantly, of the 60 HD patients, 21 individuals had an antibody response <29 BAU/ml 3 months after two vaccine doses (“low/non- responders”). Their antibody titer measured 6 weeks after administration of the booster shot showed a certain amount of antibody response. Three HD patients could still be classified as low/non-responders after their 3D. Of these, one suffered from plasmocytoma and another from myasthenia gravis, both conditions with consequences or therapies that could negatively influence B cell function. One low responder achieved an antibody titer of 67 BAU/ml, all 18 remaining patients achieved an antibody titer of 700 BAU/ml or greater (see Table 2), constituting a significant increase caused by the booster vaccine ($p < 0.001$, Mann-Whitney U).

Patient Code	Roche RBD Antibody Titer (BAU/ml)	
	pre-booster	Post-booster
241	<15	<15
209	<15	<15
266	<15	<15
253	<15	67
262	<15	719
251	<15	1840
250	<15	2793
212	<15	6657
242	<15	3963
288	<15	3988
227	<15	6292
255	<15	4043
279	<15	3358
224	<15	25000
265	<15	11698
238	19	8044
249	23	11591
276	24	15650
274	26	7465

226	28	6212
228	28	2227

Table 2. SARS-CoV-2 S antibody titers in low/non- responders on the day of and 4 weeks after the booster shot. Patient codes were assigned randomly during anonymization. All titer values in BAU/ml (binding antibody units per milliliter).

When comparing the SARS-CoV-2 RBD-specific antibody response 6–8 weeks after the 3D in the control and HD patient responder groups, no significant difference was observed ($p = 0.8$), which was in contrast to after the second vaccine dose. However, significantly lower antibody titers were found for HD patients low/non-responders after the 3D compared to the control and HD patient responder group ($p < 0.0001$, see Figure 4).

3.1.1 Influences of sex and age on antibody titer

We assessed the influence of variables known to play a role in the antibody response, namely, sex¹⁴ and age^{7,15} in our groups via a quantile regression test (see Section 2.5). In this study group, men had lower median SARS-CoV-2 RBD-specific titers than women, but this difference was not significant ($p = 0.27$). Age has a significant influence on antibody titer ($p = 0.01$): With increasing age, the median antibody titer values decrease. The Spearman correlation coefficient for the two variables age and titer was -0.28.

After including these variables in a multivariate analysis to adjust for sex and age differences in our groups, the differences in antibody titers 6–8 weeks after 3D between the low/non-responders and the other two groups were still significant ($p < 0.0001$). The control group and

the responder HD patients still did not show a significant titer difference ($p = 0.43$), and age still had a significant influence on the titers ($p = 0.33$).

Contrast	Estimate	SE	Statistic	P-value
Controls vs Dialysis responder	2158	3457	0.624	0.8071
Controls vs Dialysis low/non-responder	17386	2606	6.672	<0.0001(*)
Dialysis responder vs Dialysis low/non-responder	-15228	3173	-4.800	<0.0001(*)

Table 4. Estimated contrasts of the pairwise group comparison of SARS-CoV-2 antibody titers 6–8 weeks after 3D. All numbers, except for the p-value, are in binding antibody units per ml. $P < 0.05$ were considered significant. (), significant value.*

3.2 INF- γ titers

As a correlate of T cell activation, we compared the SARS-CoV-2-specific INF- γ response in controls ($n = 24$), HD patient responders ($n = 17$) and HD patients low/non-responder ($n = 20$) 6–8 weeks after the booster vaccine. In all, 96% (23/24) of the controls and 76% (28/37) of the HD patients that were tested developed an INF- γ titer greater than the cut-off (3 pg/ml). The boxplots (see Figure 5) show apparent differences in the distribution of INF- γ secretion between the three groups. The quantile regressions results revealed a significant difference only for the median of the control group versus low/non-responder HD patients. However, the sample sizes per group were rather small and the chosen analysis strategy (Tukey test for pairwise comparison) further reduced the power. In the multivariate analysis, neither age nor sex had a significant influence on INF- γ titers.

3.3 Adverse events (AEs) after 3D

Adverse event (AE) reports were analyzed and compared descriptively between the two groups. Sixty-one control group questionnaires and 37 HD patient questionnaires were available. No Grade 4 (emergency department visit or hospitalization) AEs were reported in either group. The control group reported more local AEs after their 3D (67% vs. 62% AEs) and more systemic AEs after the 3D (69% vs 32% AEs) compared to the HD patients (responders and low/non-responders combined) group. See Figures 6a and 6b for a graphical representation.

4. Discussion

We investigated the SARS-CoV-2-specific RBD titers in healthy controls and HD patients 6–8 weeks after 3D. Recently we showed a significant difference in titers between healthy controls and HD patients after two vaccine doses⁷. More HD patients seroconverted after the 3D (97% compared to 86% after the second dose), and the antibody titers did not differ significantly between controls and responder HD patients. Overall, antibody titers, which are an important factor in protection from a severe infection course, improved significantly after 3D in HD patients, even in low/non-responder HD patients. This result contradicts the finding of ⁸, where antibody titers in high responders did not improve significantly; however, the study's cut-off for low/non-responders was higher than in our design.

We measured SARS-CoV-2 antibody titers without neutralizing capacity or neutralization titers in our study. This could be viewed as a limitation; however, antibody titers are relevant, as demonstrated by recent studies focusing on the correlates of protection from severe infection. In nonhuman primates, after mRNA vaccine immunization¹⁶ and in adoptive transfer studies¹⁷, antibodies were identified as one such correlate. The assay we used in this paper, an RBD-specific S antibody ELISA, not only correlates with neutralization tests, it was concluded that S-specific and/or RBD-specific antibody tests can be used as a correlate of protection from

severe infection¹⁶. This conclusion is further reinforced by data on immunization with the AstraZeneca¹⁸ and mRNA-1273¹⁹ vaccines. Another study showed a better correlation of the vaccine efficacy of seven different COVID-19 vaccines with binding (S) antibody titers than with neutralization assays²⁰. It also provides data from human monoclonal therapy that proves the protective role of antibodies in COVID-19²⁰. The RBD antibody test used in our study also showed good correlation with the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody^{21,22}, thus providing standardized results.

Cut-offs to quantify antibody titers were determined as in our previous study⁷ according to correlation with a neutralization test¹⁰. Briefly, a serum antibody titer of 29 U/ml 3 weeks after the second vaccine dose was used as the cut-off to divide responder HD patients and low/non-responder HD patients. We feel that these data support the use of antibody titers as a correlate of protection and the cut-off for our groups.

Another possible limitation of our study is the usage of different vaccines (Comirnaty or Spikevax) for the 3D. This circumstance arose due to patient preference and vaccine availability and could potentially lead to differences in antibody titers. Studies show that while Spikevax boosters induce a slightly higher antibody response²³, the effectiveness of mRNA vaccines against severe disease caused by the SARS-CoV-2 Omicron variant is comparable²⁴.

T cell-mediated immunity and immunological memory against SARS-CoV-2 is deemed more robust and longer lasting than antibody levels after infection²⁵ and more consistent against variants of concern, also after vaccination with mRNA vaccines²⁶⁻³¹. It is known that the T cell response has clinical implications. Studies have shown a protective cross-reactivity between SARS-CoV-2 and endemic human coronaviruses for memory T cells³². T cell numbers of SARS-CoV-2-specific T cells in peripheral blood predict protection in individuals with low anti-S IgG responses³³. IGRA assays can be used as a clinically relevant marker of T cell activation⁶. Vaccines induce a highly conserved T cell immunity that is able to neutralize the Omicron^{34,35} and other variants, potentially even future mutations³⁶. In our study, although most of the study participants who were tested (96% of the control and 76% of the HD patients

group) developed a SARS-CoV-2-specific INF- γ response after the 3D, INF- γ titers were significantly lower in low/non-responders HD patients. As the Omicron variant rises to become the dominant pandemic strain, this could become a potential problem. SARS-CoV-2 Omicron seems to have developed a significant level of immune evasion against antibodies elicited by other variants or vaccines, effectively reducing the neutralizing capacity of serum³⁷, but the virus epitopes targeted by T cells remained relatively constant. Studies show a conserved T cell response against Omicron, whereas B cell/antibody responses against the variant and its sublineages are diminished^{38,39}. Thus, T cell responses could be more important in combatting Omicron. Since low/non-responder HD patients' INF- γ titers are lower than those of controls and responder HD patients, they may be even more susceptible to symptomatic and severe infection and/or have a higher mortality than controls and responder HD patients when confronted with this virus variant.

One limitation of our study is that our T cell test system tested INF- γ production of cells in the blood of patients. The majority of INF- γ is produced by T cells, but B cells and antigen presenting cells can also secrete INF- γ ⁴⁰, and no further differentiation of the T cell response is possible with this test. Nevertheless, in concordance with the literature cited above, we feel confident that the IGRA test can be used as an accurate tool for T cell response and that our test systems are valid surrogate markers for a protective immune response achieved by vaccination.

AEs were less pronounced in HD patients than in the control group; no severe AEs (myocarditis, emergency department visits) were reported. The 3D was well tolerated by both controls and HD patients, which agrees with data from recent studies⁸ and the general safety profile of mRNA vaccines⁴¹.

In summary, data show that HD patients like those in our study are at a high risk of infection with SARS-CoV-2 and a severe course of disease and mortality.⁴²⁻⁴⁵ Most HD-Patients developed a robust antibody response after their 3D. Seroconversion improved from 86% to 97% in HD patients. The antibody titers induced by 3D in the HD patient responder group were

not significantly lower than the antibody response in our healthy control group after the 3D. Low/non-responder HD patients developed a significantly lower antibody response compared to controls and HD patient responders after the 3D. Nonetheless, their antibody titers improved compared to after two vaccine doses. The responder HD patients' INF- γ production was equal to that of controls, but low/non-responder HD patients have significantly lower INF- γ production than the other two groups. Taken together, these findings underline that booster vaccination is a valid strategy to enhance immune responses in most HD patients to the level of healthy controls. They also point to a vulnerable group that needs a different vaccine regimen and/or preventative measures beyond vaccination (e.g., masks, social distancing and hand hygiene, testing strategies and patient isolation). Further studies on alternative vaccination strategies (e.g., dosing and scheduling) in HD patients should be conducted to protect this group from severe SARS-CoV-2 infection.

5. Disclosure Statement

The authors have no conflict of interest to disclose.

References

1. US National Institute of Health. Clinical Spectrum of SARS-CoV-2 Infection. <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/>. Updated October 19, 2021. Accessed February 18, 2022.
2. Thaunat O, Legeai C, Anglicheau D, et al. IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT). *Kidney Int.* 2020;98(6):1568-1577. doi:10.1016/j.kint.2020.10.008.
3. Quintaliani G, Reboldi G, Di Napoli A, et al. Exposure to novel coronavirus in patients on renal replacement therapy during the exponential phase of COVID-19 pandemic: survey of the Italian Society of Nephrology. *Journal of Nephrology.* 2020;33(4):725-736. doi:10.1007/s40620-020-00794-1.
4. Goffin E, Candellier A, Vart P, et al. COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study. *Nephrol Dial Transplant.* 2021;36(11):2094-2105. doi:10.1093/ndt/gfab200.
5. Wilde B, Korth J, Jahn M, Kribben A. COVID-19 vaccination in patients receiving dialysis. *Nature Reviews Nephrology.* 2021;17(12):788-789. doi:10.1038/s41581-021-00499-z.
6. Espi M, Charmetant X, Barba T, et al. The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients

- receiving maintenance hemodialysis. *Kidney Int.* 2021;100(4):928-936.
doi:10.1016/j.kint.2021.07.005.
7. Simon B, Rubey H, Treipl A, et al. Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared to healthy controls. *Nephrol Dial Transplant.* 2021. doi:10.1093/ndt/gfab179.
8. Espi M, Charmetant X, Barba T, et al. A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis. *Kidney Int.* 2021. doi:10.1016/j.kint.2021.10.040.
9. Fischer K, Holzmann H, Karthaler U, et al. COVID-19-Impfungen: Anwendungsempfehlungen des Nationalen Impfgremiums.
file:///C:/Users/misimobe/Downloads/COVID-19-Impfungen__Anwendungsempfehlung__des_Nationalen_Impfgremiums_6.1_(Stand__22.11.pdf. Updated November 22, 2021. Accessed December 13, 2021.
10. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. *Nature Biotechnology.* 2020;38(9):1073-1078. doi:10.1038/s41587-020-0631-z.
11. Wantai Biopharm Co. Ltd. WANTAI SARS-CoV-2-IGRA: Diagnostic Kit for T Cell activity to SARS-CoV-2 Product Information. https://www.szabo-scandic.com/pub/media/product_data/datasheet/WAN/WAN-DATA-WANWS-1696.pdf. Accessed September 8, 2021.
12. U.S. Department of Health and Human Services. Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.
<https://www.fda.gov/media/73679/download>. Updated May 17, 2019. Accessed December 22, 2021.
13. R Core Team. R: A language and environment for statistical computing. <https://www.R-project.org/>. Accessed February 3, 2022.
14. Ciarambino T, Para O, Giordano M. Immune system and COVID-19 by sex differences and age. *Womens Health (Lond).* 2021;17:17455065211022262-17455065211022262. doi:10.1177/17455065211022262.
15. Cheng ZJ, Xue M, Zheng P, et al. *Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review*; 2021. Vaccines; 9.
16. Corbett KS, Nason MC, Flach B, et al. Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates. *bioRxiv.* 2021. doi:10.1101/2021.04.20.440647.
17. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature.* 2021;590(7847):630-634. doi:10.1038/s41586-020-03041-6.
18. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *medRxiv.* 2021:2021.06.21.21258528. doi:10.1101/2021.06.21.21258528.
19. Gilbert PB, Montefiori DC, McDermott A, et al. Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. *medRxiv.* 2021. doi:10.1101/2021.08.09.21261290.
20. Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. *Nature Medicine.* 2021;27(7):1147-1148. doi:10.1038/s41591-021-01432-4.
21. WHO. WHO/BS.2020.2403 Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody. Updated November 18, 2020.
22. Rubio-Acero R, Castelletti N, Fingerle V, et al. In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-

- characterized Oligo-/Asymptomatic Patients. *Infect Dis Ther.* 2021;10(3):1505-1518. doi:10.1007/s40121-021-00475-x.
23. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. *The Lancet.* 2021;398(10318):2258-2276. doi:10.1016/S0140-6736(21)02717-3.
24. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19—Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022. *MMWR Morb Mortal Wkly Rep.* 2022;(71):139-145. <http://dx.doi.org/10.15585/mmwr.mm7104e3>. Accessed January 27, 2022.
25. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science.* 2021;371(6529). doi:10.1126/science.abf4063.
26. Redd AD, Nardin A, Kared H, et al. CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants. *Open Forum Infectious Diseases.* 2021;8(7). doi:10.1093/ofid/ofab143.
27. Tarke A, Sidney J, Methot N, et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. *Cell Reports Medicine.* 2021;2(7):100355. doi:10.1016/j.xcrm.2021.100355.
28. Geers D, Shamier MC, Bogers S, et al. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. *Sci Immunol.* 2021;6(59). doi:10.1126/sciimmunol.abj1750.
29. Goel RR, Painter MM, Apostolidis SA, et al. mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern. *bioRxiv.* 2021:2021.08.23.457229. doi:10.1101/2021.08.23.457229.
30. Painter MM, Mathew D, Goel RR, et al. Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. *Immunity.* 2021. doi:10.1016/j.immuni.2021.08.001.
31. Liu J, Chandrashekar A, Sellers D, et al. Vaccines Elicit Highly Conserved Cellular Immunity to SARS-CoV-2 Omicron. *Nature.* 2022. doi:10.1038/s41586-022-04465-y.
32. Kundu R, Narean JS, Wang L, et al. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. *Nat Commun.* 2022;13(1):80. doi:10.1038/s41467-021-27674-x.
33. Wyllie D, Jones HE, Mulchandani R, et al. SARS-CoV-2 responsive T cell numbers and anti-Spike IgG levels are both associated with protection from COVID-19: A prospective cohort study in keyworkers. *medRxiv.* 2021:2020.11.02.20222778. doi:10.1101/2020.11.02.20222778.
34. Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. *Nature.* 2022. doi:10.1038/s41586-022-04460-3.
35. Moss P. The T cell immune response against SARS-CoV-2. *Nature Immunology.* 2022;23(2):186-193. doi:10.1038/s41590-021-01122-w.
36. Tarke A, Coelho CH, Zhang Z, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. *Cell.* 2022. doi:10.1016/j.cell.2022.01.015.

37. Schmidt F, Muecksch F, Weisblum Y, et al. Plasma neutralization properties of the SARS-CoV-2 Omicron variant. *medRxiv*. 2021:2021.12.12.21267646. doi:10.1101/2021.12.12.21267646.
38. Tarke A, Coelho CH, Zhang Z, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. *Cell*. doi:10.1016/j.cell.2022.01.015.
39. Iketani S, Liu L, Guo Y, et al. Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages. *bioRxiv*. 2022:2022.02.07.479306. doi:10.1101/2022.02.07.479306.
40. Burke JD, Young HA. IFN- γ : A cytokine at the right time, is in the right place. *Semin Immunol*. 2019;43:101280. doi:10.1016/j.smim.2019.05.002.
41. Hause AM, Baggs J, Marquez P, et al. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022. *MMWR Morb Mortal Wkly Rep*. 2022;(71). <http://dx.doi.org/10.15585/mmwr.mm7109e2>.
42. Windpessl M, Bruchfeld A, Anders H-J, et al. COVID-19 vaccines and kidney disease. *Nat Rev Nephrol*. 2021;1-3. doi:10.1038/s41581-021-00406-6.
43. Francis A, Baigent C, Ikizler TA, Cockwell P, Jha V. The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action. *Kidney Int*. 2021;99(4):791-793. doi:10.1016/j.kint.2021.02.003.
44. Hilbrands LB, Duivenvoorden R, Vart P, et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. *Nephrol Dial Transplant*. 2020;35(11):1973-1983. doi:10.1093/ndt/gfaa261.
45. Jager KJ, Kramer A, Chesnaye NC, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. *Kidney Int*. 2020;98(6):1540-1548. doi:10.1016/j.kint.2020.09.006.
46. Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.




Figure 2. Antibody titers in healthy controls over the course of approximately 1 year. Booster vaccine doses were applied in October 2021. All values in binding antibody units per milliliter.




Figure 3. Antibody titers in all hemodialysis (HD) patients (responder and low/non-responder combined) over the course of approximately 1 year. Booster vaccine doses were applied in October 2021. All values in binding antibody units per milliliter.




Figure 5. Interferon gamma secretion IGRA titers in Controls and HD Patients (split into responder and low/non-responder) 6–8 weeks after the third vaccine dose. Interferon gamma titers in picograms per ml. HD-P, HD patients. P values < 0.05 were considered significant. *n.s.*, not significant.




Figure 6a, local adverse events (AEs) after the third vaccination. All numbers represent the percentages of dialysis (n = 36) and control (n = 61) patients. The AEs were recorded using a standardized questionnaire and graded by the patients (Grade 1: mild, does not interfere with activity; Grade 2: moderate, interferes with activity; Grade 3: severe, prevents daily activity). No Grade 4 events (emergency department visits or hospitalization) were reported. HD patients, patients on hemodialysis.




Figure 6b, systemic adverse events (AEs) after the third vaccination. All numbers represent the percentages of dialysis (n = 36) and control (n = 61) patients. The AEs were recorded using a standardized questionnaire and graded by the patients (Grade 1: mild, does not interfere with activity; Grade 2: moderate, interferes with activity; Grade 3: severe, prevents daily activity). No Grade 4 events (emergency department visits or hospitalization) were reported. HD patients, patients on hemodialysis; GI, gastrointestinal AEs (diarrhea, nausea and vomiting).




Figure 1, patient flowchart. This flowchart is a graphical representation of the study design. The time axis on the left shows various significant time points in the study for easy orientation. The column beside the time points lists the events that occurred at this time point. Entries in this column are explained in the box at the bottom right of the flowchart.




Figure 4, SARS-CoV-2 receptor binding domain-specific antibody titers in Controls and hemodialysis patients (HD Patients, split into responder and low/non- responder groups) 6 months after the second vaccine dose (left) and 6-8 weeks after the third vaccine dose (right). Antibody titres in BAU (binding antibody units) per millilitre. P values <0.05 were considered significant. n.s., not significant. The p value in the left figure is for Controls vs. all HD Patients (responders and low/non- responders combined).